Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer

Paclitaxel is one of the most effective chemotherapy drugs for breast cancer worldwide but 20–30% patients show primary resistance to the drug. Screening and identification of markers that facilitate effective and rapid prediction of sensitivity to paclitaxel is therefore an urgent medical requireme...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhe, Li, Zhi, Deng, Mingming, Liu, Bofang, Xin, Xing, Zhao, Zhenkun, Zhang, Ye, Lv, Qingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041173/
https://www.ncbi.nlm.nih.gov/pubmed/32020211
http://dx.doi.org/10.3892/or.2020.7471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041173/
https://www.ncbi.nlm.nih.gov/pubmed/32020211
http://dx.doi.org/10.3892/or.2020.7471

Ejemplares similares